• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型抗血小板化合物α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯的手性拆分

Chiral resolution of alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene, a novel antiplatelet compound.

作者信息

Gollamudi R, Feng Z X

机构信息

Department of Medicinal Chemistry, College of Pharmacy, University of Tennessee-Memphis 38163.

出版信息

Chirality. 1991;3(6):480-3. doi: 10.1002/chir.530030613.

DOI:10.1002/chir.530030613
PMID:1812959
Abstract

alpha,alpha'-Bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide, a novel antiplatelet agent, was resolved into three isomers A, B, and C, on a chiral alpha 1-acid glycoprotein analytical column using a mobile phase of 0.025 M phosphate buffer containing 0.025 M tetrabutylammonium hydrogen sulfate, at a pH of 6.5. The effect of molarity, temperature, pH, flow rate, and organic modifiers on the enantioselectivity was examined. Based on circular dichroic spectra at 220 nm, A and C appear to be the (-)- and (+)-enantiomers, respectively, and B the meso diastereomer. Attempts at resolution using Pirkle type columns gave unsatisfactory results. It appears that both hydrophobic and polar interactions between the compound and the stationary phase are important determinants of resolution.

摘要

新型抗血小板药物α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯二氢溴化物在含有0.025 M硫酸氢四丁铵的0.025 M磷酸盐缓冲液(pH 6.5)流动相的手性α1-酸性糖蛋白分析柱上被拆分为三种异构体A、B和C。研究了摩尔浓度、温度、pH、流速和有机改性剂对 enantioselectivity 的影响。基于220 nm处的圆二色光谱,A和C似乎分别是(-)-和(+)-对映体,B是内消旋非对映体。使用Pirkle型柱进行拆分的尝试得到了不理想的结果。看来化合物与固定相之间的疏水和极性相互作用都是拆分的重要决定因素。

相似文献

1
Chiral resolution of alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene, a novel antiplatelet compound.新型抗血小板化合物α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯的手性拆分
Chirality. 1991;3(6):480-3. doi: 10.1002/chir.530030613.
2
Chiral separation of nipecotic acid amides.
J Chromatogr. 1992 Sep 18;609(1-2):187-93. doi: 10.1016/0021-9673(92)80162-n.
3
In vitro and in vivo activities of the novel antiplatelet agent alpha,alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide.新型抗血小板药物α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯二氢溴化物的体外和体内活性
Res Commun Chem Pathol Pharmacol. 1992 Dec;78(3):279-88.
4
Synthesis of stereoisomers of antithrombotic nipecotamides.抗血栓形成的氮杂环丁酰胺立体异构体的合成。
Chirality. 1995;7(2):90-5. doi: 10.1002/chir.530070207.
5
Enantioselective antiplatelet actions of nipecotamides.烟酰胺类化合物的对映选择性抗血小板作用。
Thromb Res. 1993 Feb 15;69(4):361-7. doi: 10.1016/0049-3848(93)90035-m.
6
Antiplatelet effects of R,S-(meso)-alpha, alpha'-bis[3-(N,N-diethylcarbamoyl) piperidino]-p-xylene ex vivo in the dog and in vivo in the mouse.R,S-(内消旋)-α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯在犬体内外及小鼠体内的抗血小板作用
Gen Pharmacol. 1997 Apr;28(4):617-21. doi: 10.1016/s0306-3623(96)00272-8.
7
Antiplatelet agents affecting the interaction of Tissue Factor-Factor VIIa complex with Factor X in a continuous-flow reactor.在连续流动反应器中影响组织因子-因子VIIa复合物与因子X相互作用的抗血小板药物。
Biotechnol Appl Biochem. 1996 Feb;23(1):63-6.
8
Preliminary in vivo studies on the platelet aggregation inhibitory activity of alpha, alpha'-bis[3-(N,N-diethylcarbamoyl)piperidino]-p-xylene dihydrobromide in beagle dogs.α,α'-双[3-(N,N-二乙基氨基甲酰基)哌啶基]-对二甲苯二氢溴化物对比格犬血小板聚集抑制活性的初步体内研究。
J Pharm Sci. 1988 May;77(5):464-5. doi: 10.1002/jps.2600770523.
9
Chiral resolution of flurbiprofen and ketoprofen enantiomers by HPLC on a glycopeptide-type column chiral stationary phase.在糖肽型柱手性固定相上通过高效液相色谱法对氟比洛芬和酮洛芬对映体进行手性拆分。
Biomed Chromatogr. 2001 May;15(3):217-22. doi: 10.1002/bmc.65.
10
Inhibition of PAF-induced human platelet aggregation by antithrombotic nipecotomides.抗血栓形成的尼哌替丁类化合物对血小板活化因子诱导的人血小板聚集的抑制作用
Prostaglandins Leukot Essent Fatty Acids. 1995 May;52(5):309-18. doi: 10.1016/0952-3278(95)90032-2.